ocrelizumab – an important therapeutic option in the treatment of patients with multiple sclerosis. American Academy of Neurology – Update 2019 Meeting Proceedings
Article Sidebar
Published:
Jun 30, 2019
Keywords:
multiple sclerosis, immunomodulatory therapy, monoclonal antibody, ocrelizumab
Main Article Content
Abstract
The paper reviews reports presented during the annual Congress of the American Academy of Neurology regarding multiple sclerosis therapy with the use of ocrelizumab.
Based on the review, it can be concluded that the treatment with ocrelizumab is both highly effective and the safety profile is not in any doubt. At present, it is the only drug used in the form of a primarily progressively progressive multiple sclerosis.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Charakterystyka Produktu Leczniczego. Ocrevus [online] .
2. Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376(3): 209-220.
3. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376(3): 221-234.
4. Leist T, Reder A, Bermel R et al. One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract: S56-007.
5. Cross A, Bennett J, von Büdingen HC et al. Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract. S56-008.
6. Naismith R, Coyle P, Saidha S et al. Influence of Gender and Age in Use of Ocrelizumab for PPMS Patients Among US Neurologists. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P1.2-102.
7. Wolinsky J, Kappos L, Montalban X, Model F. Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract S3.2-031.
8. Arnold DL, Giovannoni G, Hartung HP et al. Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Okrelizumab Later: Results of ORATORIO 5-Year Follow-Up. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-042.
9. Hauser SL, Kappos L, Montalban X et al. Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-054.
10. Giovannoni G, Airas L, Bove R et al. Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-091.
11. Kletzl H, Gibiansky E, Petry C et al. Pharmacokinetics, Pharmacodynamics and Exposure-Response Analyses of Ocrelizumabein Patients With Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract N4-001.
12. Vollmer T, Alvarez E, Nair K et al. Evaluation of shorter infusion times with ocrelizumabin patients with relapsing-remitting multiple sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-034.
13. Alimohamadi S, Vollmer B, Nair K et al. Ocrelizumab Safety and Effectiveness in the One Year Treatment of Multiple Sclerosis Compared to Other Disease Modifying Therapies. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-053.
14. Moss B, Parrotta E, Baldassari L et al. Real-World Experience with Ocrelizumab. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-059.
15. Alvarez E, Nair K, Shelton I et al. Evaluating the Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P 4.2-015.
16. Hauser S, Kappos L, Montablan X et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive Multiple sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P4.2-025.
17. Wormser D, Evershed J, Ferreira G et al. VERISMO: A Post-Marketing Safety Study to Determine the Incidence of All Malignancies and Breast Cancer in Patients With Multiple Sclerosis Treated With Ocrelizumab. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P 4.2-043.
2. Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376(3): 209-220.
3. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376(3): 221-234.
4. Leist T, Reder A, Bermel R et al. One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract: S56-007.
5. Cross A, Bennett J, von Büdingen HC et al. Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract. S56-008.
6. Naismith R, Coyle P, Saidha S et al. Influence of Gender and Age in Use of Ocrelizumab for PPMS Patients Among US Neurologists. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P1.2-102.
7. Wolinsky J, Kappos L, Montalban X, Model F. Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract S3.2-031.
8. Arnold DL, Giovannoni G, Hartung HP et al. Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Okrelizumab Later: Results of ORATORIO 5-Year Follow-Up. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-042.
9. Hauser SL, Kappos L, Montalban X et al. Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-054.
10. Giovannoni G, Airas L, Bove R et al. Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-091.
11. Kletzl H, Gibiansky E, Petry C et al. Pharmacokinetics, Pharmacodynamics and Exposure-Response Analyses of Ocrelizumabein Patients With Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract N4-001.
12. Vollmer T, Alvarez E, Nair K et al. Evaluation of shorter infusion times with ocrelizumabin patients with relapsing-remitting multiple sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-034.
13. Alimohamadi S, Vollmer B, Nair K et al. Ocrelizumab Safety and Effectiveness in the One Year Treatment of Multiple Sclerosis Compared to Other Disease Modifying Therapies. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-053.
14. Moss B, Parrotta E, Baldassari L et al. Real-World Experience with Ocrelizumab. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-059.
15. Alvarez E, Nair K, Shelton I et al. Evaluating the Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P 4.2-015.
16. Hauser S, Kappos L, Montablan X et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive Multiple sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P4.2-025.
17. Wormser D, Evershed J, Ferreira G et al. VERISMO: A Post-Marketing Safety Study to Determine the Incidence of All Malignancies and Breast Cancer in Patients With Multiple Sclerosis Treated With Ocrelizumab. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P 4.2-043.